Trial Profile
Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs RDEA 806 (Primary)
- Indications Gout
- Focus Therapeutic Use
- 24 May 2012 Planned number of patients changed from 30 to 60 and additional trial locations (Spain, Belgium) added as reported by European Clinical Trials Database.
- 09 Oct 2009 Planned end date changed from 1 Apr 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 21 Apr 2009 Status changed from recruiting to completed; results reported in an Ardea Biosciences media release.